Recovery from Anesthesia after Robotic-Assisted Radical Cystectomy: Two Different Reversals of Neuromuscular Blockade

Area of Science:

• Anesthesiology
• Surgical Oncology
• Neurosurgery

Background:

• Robot-assisted radical cystectomy (RARC) involves challenging surgical conditions that can negatively impact patient outcomes.
• Postoperative nausea and vomiting (PONV) and ileus are common complications following RARC.
• Cognitive function can be affected in the immediate postoperative period.

Purpose of the Study:

• To compare the incidence of PONV and ileus between sugammadex and neostigmine reversal agents in RARC patients.
• To evaluate the quality of cognitive function upon awakening in patients receiving sugammadex versus neostigmine.
• To assess the time to resumption of intestinal transit after different neuromuscular blockade reversals.

Main Methods:

• A randomized trial involving 109 patients undergoing RARC for bladder cancer.
• Patients were randomized to receive either sugammadex (S group) or neostigmine + atropine (N group) for neuromuscular blockade reversal.
• PONV, cognitive function (Mini-Mental State test), and intestinal transit were assessed post-surgery.

Main Results:

• The incidence of early PONV was not significantly different between the sugammadex and neostigmine groups (25.9% vs. 29%, p = 0.711).
• Patients in the sugammadex group demonstrated significantly higher Mini-Mental State test scores at 1 hour (p = 0.007) and 4 hours (p = 0.05) post-surgery compared to the neostigmine group.
• No significant decrease in PONV was observed with sugammadex compared to neostigmine.

Conclusions:

• Sugammadex administration resulted in better cognitive function recovery in patients undergoing RARC compared to neostigmine.
• While early PONV rates were similar, sugammadex shows a potential benefit in preserving cognitive function post-RARC.
• Further research may explore optimal reversal strategies to mitigate both PONV and cognitive impairment in RARC.